Hui Shao

List of Publications by Year
in descending order

46 papers	658 citations	623734 14 h-index	642732 23 g-index
48 all docs	48 docs citations	48 times ranked	910 citing authors

#	Article	IF	Citations
1	Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). Pharmacoeconomics, 2018, 36, 1125-1134.	3.3	61
2	Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review. Pharmacoeconomics, 2018, 36, 17-27.	3.3	51
3	Is hypoglycemia fear independently associated with health-related quality of life?. Health and Quality of Life Outcomes, 2014, 12, 167.	2.4	45
4	Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005â€“2007 and 2015â€“2017. Diabetes Care, 2020, 43, 2396-2402.	8.6	37
5	Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. Pharmacoeconomics, 2019, 37, 921-929.	3.3	35
6	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value in Health, 2020, 23, 1163-1170.	0.3	32
7	Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. Pharmacoeconomics, 2019, 37, 777-818.	3.3	30
8	Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current Medical Research and Opinion, 2017, 33, 359-369.	1.9	29
9	Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: Meta-analysis of correlational evidence. Journal of Diabetes and Its Complications, 2019, 33, 107409.	2.3	25
10	A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. Current Diabetes Reports, 2020, 20, 12.	4.2	21
11	Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTsâ€™ Access in Multiple Sclerosis. Value in Health, 2018, 21, 1083-1089.	0.3	18
12	Income, Relative Deprivation and the Self-Rated Health of Older People in Urban and Rural China. Frontiers in Public Health, 2021, 9, 658649.	2.7	18
13	Estimating costs of diabetes complications in people <65â€¯years in the U.S. using panel data. Journal of Diabetes and Its Complications, 2020, 34, 107735.	2.3	17
14	Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodiumâ€“Glucose Transporter 2 Inhibitors. Diabetes Care, 2020, 43, 1530-1536.	8.6	16
15	Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). Diabetes Research and Clinical Practice, 2018, 140, 45-54.	2.8	15
16	Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. JAMA Network Open, 2022, 5, e227705.	5.9	15
17	Association between frailty and life satisfaction among older people in Shandong, China: the differences in age and general selfâ€efficacy. Psychogeriatrics, 2020, 20, 172-179.	1.2	14
18	Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study. Journal of Diabetes and Its Complications, 2021, 35, 107972.	2.3	14

#	Article	IF	Citations
19	Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. Journal of Medical Economics, 2015, 18, 974-989.	2.1	13
20	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. Value in Health, 2019, 22, 1402-1409.	0.3	13
21	Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. BMC Medicine, 2020, 18, 378.	5.5	13
22	An exploratory spatial analysis of overweight and obesity among children and adolescents in Shandong, China. BMJ Open, 2019, 9, e028152.	1.9	11
23	The impact of a bundled policy intervention on improving the performance of rural healthcare in China. International Journal for Equity in Health, 2016, 15, 46.	3.5	10
24	Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis. Diabetes Care, 2019, 42, 2136-2142.	8.6	10
25	Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study. Journal of Clinical Medicine, 2020, 9, 2332.	2.4	9
26	Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. Diabetes Care, 2020, 43, 2847-2852.	8.6	9
27	Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018. Diabetes Care, 2021, 44, 925-934.	8.6	7
28	Estimating benefit equity of government health subsidy in healthcare Services in Shandong Province, China: a cross-sectional study. International Journal for Equity in Health, 2018, 17, 61.	3.5	6
29	Predicting incident heart failure among patients with type 2 diabetes mellitus: The <scp>DMâ€CURE</scp> risk score. Diabetes, Obesity and Metabolism, 2022, 24, 2203-2211.	4.4	6
30	Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study. Journal of Diabetes and Its Complications, 2021, 35, 107839.	2.3	4
31	Newer <scp>glucoseâ€lowering</scp> drugs and risk of dementia: A <scp>metaâ€analysis</scp> of cardiovascular outcome trials. Journal of the American Geriatrics Society, 2022, 70, 2719-2722.	2.6	4
32	Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare. Diabetes Care, 2022, 45, 1814-1821.	8.6	4
33	Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018. Diabetes Care, 2021, , dc202529.	8.6	3
34	Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes. Diabetes Care, 2022, 45, e32-e33.	8.6	3
35	Mapping and Analyzing Stakeholders in Chinaâ€™s Essential Drug System by Using a Circular Model: Who We Should Deal with Next?. Value in Health Regional Issues, 2015, 6, 111-117.	1.2	2
36	Does the Encounter Type Matter When Defining Diabetes Complications in Electronic Health Records?. Medical Care, 2020, 58, S53-S59.	2.4	2

#	Article	IF	Citations
37	Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study. Journal of Diabetes and Its Complications, 2022, 36, 108132.	2.3	2
38	Selecting a target population for type 2 diabetes lifestyle prevention programs: A costâ€effectiveness perspective. Diabetic Medicine, 2022, , e14847.	2.3	2
39	Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298â€“2306. Diabetes Care, 2020, 43, e25-e25.	8.6	1
40	Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimerâ€™s disease and related dementias (ADRD). Current Medical Research and Opinion, 2021, 37, 1731-1737.	1.9	1
41	Projecting Long-Term Diabetes Complications through a BRAVO-Based Mock Simulation for Promoting Diabetes Prevention Program (DPP). Diabetes, 2018, 67, 701-P.	0.6	1
42	9-OR: Cost Effectiveness of the New 2018 ACP Glycemic Control Guideline among U.S. Adults with Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	1
43	A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015. Value in Health, 2022, , .	0.3	1
44	Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes. Value in Health, 2021, 24, 227-235.	0.3	0
45	A varied approach to left ventricular assist device follow-up improves cost-effectiveness. Current Medical Research and Opinion, 2021, 37, 1501-1505.	1.9	0
46	The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010â€“2018. Current Medical Research and Opinion, 2021, 37, 1-6.	1.9	0